From 2016-2025, Jay led AbbVie’s Business Development and Acquisitions team as Vice President, Head of BD&A. Jay and the business development & acquisitions team he led executed a large variety of transactions, ranging from the $63b acquisition of Allergan in 2019 to a multitude of product development, collaboration, option or technology platform deals and acquisitions across AbbVie’s key therapeutic areas. Jay and his team also were integral in the development of therapeutic area and business development strategies for core therapeutic areas including Oncology, Immunology and Neuroscience.

Prior to joining AbbVie, Jay was the Vice President of Business Development at Atara Bio, a publicly-traded oncology and cell therapy company in the San Francisco Bay Area. Preceding his tenure at Atara Bio, Jay worked at Acerta Pharma, another Bay Area oncology start-up, now a subsidiary of AstraZeneca, and Onyx Pharmaceuticals, until its acquisition by Amgen. Jay also spent a number of years at Amgen and Eli Lilly in a variety of business development and commercial leadership roles.

Jay earned his BA in History from Tulane University and an MBA from Washington University in St. Louis. He lives in the Chicago area with his wife Jean and 3 teenage sons and enjoys cycling, being outdoors and supporting his boys at a range of youth sports.